{"entity":{"id":"nct00376883","kind":"trial","name":"Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month","aka":[],"tldr":"A phase 3 trial of Pamidronate in Multiple myeloma, run by Nordic Myeloma Study Group, completed.","summary":"Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month is a phase 3 interventional study registered as NCT00376883 by Nordic Myeloma Study Group, with 500 participants recorded, started 2000-01. Interventions recorded: pamidronate. Conditions recorded: Multiple Myeloma.\n\nLinked to the drug Pamidronate because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT00376883","url":"https://clinicaltrials.gov/study/NCT00376883"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["pamidronate"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00376883","phase":"3","setting":"The Effect of i.v. Bisphosphonate on Health-Related Quality of Life and Skeletal Morbidity for Newly Diagnosed Treatment Demanding Multiple Myeloma. A Prospective Randomised Double Blinded Dose-Effective Study With Cost-Utility Analysis.","sponsor":"Nordic Myeloma Study Group","enrolled":500,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00376883/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"pamidronate","kind":"drug","name":"Pamidronate","route":"/drugs/pamidronate/"}]}}